-
Subject Areas on Research
-
A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.
-
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
-
Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers.
-
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
-
Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease.
-
Aerosolized ribavirin: the most expensive drug for pneumonia.
-
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
-
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
-
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
-
Analysis of site performance in academic-based and community-based centers in the IDEAL Study.
-
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
-
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
-
Boceprevir for HCV in patients with HIV: where next?
-
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
-
Boceprevir for untreated chronic HCV genotype 1 infection.
-
Bronchiolitis.
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.
-
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
-
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.
-
Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
-
Definition and management of anemia in patients infected with hepatitis C virus.
-
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
-
Diagnosis and treatment of chronic hepatitis C infection.
-
Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.
-
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
-
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
-
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
-
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
-
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
-
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
-
Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
-
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
-
Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
-
Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
-
Factors influencing the participation of gastroenterologists and hepatologists in clinical research.
-
Future trends in managing hepatitis C.
-
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
-
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
-
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
-
HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.
-
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.
-
Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.
-
Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.
-
Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
-
Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.
-
IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
-
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
-
IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
-
IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.
-
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
-
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
-
Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.
-
In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.
-
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
-
Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.
-
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.
-
Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
-
Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.
-
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
-
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
-
Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
-
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
-
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
-
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
-
Making it happen: managed care considerations in vanquishing hepatitis C.
-
Management of hepatitis C virus infection: the basics.
-
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
-
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.
-
New therapies for chronic hepatitis C virus infection.
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
-
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients.
-
Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients.
-
Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
-
PHOTON-2: hope for patients with HIV and HCV co-infection?
-
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
-
Pericarditis mediated by respiratory syncytial virus in a hematopoietic stem cell transplant patient.
-
PharmGKB summary: peginterferon-α pathway.
-
Pharmacologic treatment of bronchiolitis in infants and children: a systematic review.
-
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.
-
Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
-
Predictors of consent to pharmacogenomics testing in the IDEAL study.
-
Racial differences in hepatitis C treatment eligibility.
-
Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
-
Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin.
-
Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin.
-
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.
-
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
-
Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
-
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
-
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
-
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
-
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
-
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
-
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
-
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
-
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
-
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
-
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
-
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
-
Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters.
-
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
-
Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.
-
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
-
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.
-
Telaprevir for previously treated chronic HCV infection.
-
Telaprevir for the treatment of chronic hepatitis C infection.
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
-
The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA.
-
The rapid evolution of treatment strategies for hepatitis C.
-
Treatment of chronic hepatitis C in blacks and non-Hispanic whites.
-
Treatment of hepatitis C in special populations.
-
Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.
-
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
-
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
-
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
-
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.